Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report

被引：1
作者：
Mannini, Elisa [1 ]
Misirocchi, Francesco [1 ]
Lazzari, Stefania [1 ]
Balella, Giulia [1 ]
Bottignole, Dario [1 ]
Frapporti, Maddalena [1 ]
Zinno, Lucia [1 ,3 ]
Florindo, Irene [1 ,3 ]
Parrino, Liborio [1 ,2 ,3 ]
Mutti, Carlotta [1 ,2 ,3 ]
机构：
[1] Parma Univ Hosp, Dept Gen & Specialized Med, Neurol Unit, Via Gramsci 14, I-43126 Parma, Italy
[2] Parma Univ Hosp, Sleep Disorders Ctr, Dept Med & Surg, Parma, Italy
[3] Univ Parma, Interdept Ctr Sleep Med, Parma, Italy
来源：
EPILEPSY & BEHAVIOR REPORTS | 2024年 / 27卷
关键词：
Developmental epileptic encephalopathy; Quality of life; Cannabidiol; Epilepsy; Drug; -resistance; LIFE; MEDICATIONS;
D O I：
10.1016/j.ebr.2024.100687
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Developmental Epileptic encephalopathies (DEEs) are severe neurological conditions where cognitive functions appear modulated by both seizure and interictal epileptiform activity. Cannabidiol (CBD) has been shown to be highly effective in the treatment of drug-resistant seizures in patients with DEEs. Along with its antiseizure effects, CBD demonstrated clinical beneficial effects in patients' quality of life, sleep and numerous adaptive behaviors. However, based on the available phase III studies, the indications for this treatment have so far been restricted to Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC) by regulatory authorities. We present the case of a 30-year-old girl with a rare genetic DEE, experiencing relevant seizure frequency reduction together with striking improvement in sleep quality, mood, behavior, language and motor skills after introducing off-label CBD.
引用
收藏
页数：4
相关论文
共 22 条
  • [1] fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy
    Allendorfer, Jane B.
    Nenert, Rodolphe
    Bebin, E. Martina
    Gaston, Tyler E.
    Grayson, Leslie E.
    Hernando, Kathleen A.
    Houston, James T.
    Hansen, Barbara
    Szaflarski, Jerzy P.
    [J]. EPILEPSY & BEHAVIOR, 2019, 96 : 114 - 121
  • [2] Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force
    Bernasconi, Andrea
    Cendes, Fernando
    Theodore, William H.
    Gill, Ravnoor S.
    Koepp, Matthias J.
    Hogan, Robert Edward
    Jackson, Graeme D.
    Federico, Paolo
    Labate, Angelo
    Vaudano, Anna Elisabetta
    Bluemcke, Ingmar
    Ryvlin, Philippe
    Bernasconi, Neda
    [J]. EPILEPSIA, 2019, 60 (06) : 1054 - 1068
  • [3] Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy
    Besag, Frank M. C.
    Vasey, Michael J.
    [J]. PEDIATRIC DRUGS, 2021, 23 (03) : 253 - 286
  • [4] Clinical delineation of a patient with trisomy 12q23q24
    Bouman, Arjan
    Schuitema, Anke
    Pfundt, Rolph
    van de Zande, Guillaume
    Kleefstra, Tjitske
    [J]. EUROPEAN JOURNAL OF MEDICAL GENETICS, 2013, 56 (08) : 463 - 469
  • [5] The Polypharmacological Effects of Cannabidiol
    Castillo-Arellano, Jorge
    Canseco-Alba, Ana
    Cutler, Stephen J.
    Leon, Francisco
    [J]. MOLECULES, 2023, 28 (07):
  • [6] Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes
    Devinsky, Orrin
    Verducci, Chloe
    Thiele, Elizabeth A.
    Laux, Linda C.
    Patel, Anup D.
    Filloux, Francis
    Szaflarski, Jerzy P.
    Wilfong, Angus
    Clark, Gary D.
    Park, Yong D.
    Seltzer, Laurie E.
    Bebin, E. Martina
    Flamini, Robert
    Wechsler, Robert T.
    Friedman, Daniel
    [J]. EPILEPSY & BEHAVIOR, 2018, 86 : 131 - 137
  • [7] Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy
    Gaston, Tyler E.
    Szaflarski, Magdalena
    Hansen, Barbara
    Bebin, E. Martina
    Szaflarski, Jerzy P.
    [J]. EPILEPSY & BEHAVIOR, 2019, 95 : 10 - 17
  • [8] Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study
    Kuehne, Fabienne
    Becker, Lena-Luise
    Bast, Thomas
    Bertsche, Astrid
    Borggraefe, Ingo
    Bosselmann, Christian Malte
    Fahrbach, Joerg
    Hertzberg, Christoph
    Herz, Nina A.
    Hirsch, Martin
    Holtkamp, Martin
    Janello, Christine
    Kluger, Gerhard Josef
    Kurlemann, Gerhard
    Lerche, Holger
    Makridis, Konstantin L.
    von Podewils, Felix
    Pringsheim, Milka
    Schubert-Bast, Susanne
    Schulz, Juliane
    Schulze-Bonhage, Andreas
    Steinbart, David
    Steinhoff, Bernhard J.
    Strzelczyk, Adam
    Syrbe, Steffen
    De Vries, Heike
    Wagner, Christiane
    Wagner, Johanna
    Wilken, Bernd
    Prager, Christine
    Klotz, Kerstin A.
    Kaindl, Angela M.
    [J]. EPILEPSIA OPEN, 2023, 8 (02) : 360 - 370
  • [9] Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome
    Lattanzi, Simona
    Trinka, Eugen
    Striano, Pasquale
    Rocchi, Chiara
    Salvemini, Sergio
    Silvestrini, Mauro
    Brigo, Francesco
    [J]. CNS DRUGS, 2021, 35 (03) : 265 - 281
  • [10] Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy
    Nenert, Rodolphe
    Allendorfer, Jane B.
    Bebin, E. Martina
    Gaston, Tyler E.
    Grayson, Leslie E.
    Houston, James T.
    Szaflarski, Jerzy P.
    [J]. EPILEPSY & BEHAVIOR, 2020, 112
123